In tumor tissues and the dLNs, anti-TNFR2 monotherapy and combinatory therapy also significantly reduced the proportion of Foxp3+ Tregs in total T cells and decreased TNFR2 expression, with the combinatory therapy showing an augmented effect (Figure 7F). The gene discussed is FOXP3; the disease is neoplasm.